US EditionHims & Hers pulls copycat Wegovy weight-loss pill after threats of legal action
Hims & Hers halted its $49 compounded semaglutide pill after FDA and Department of Health and Human Services actions citing safety and legal concerns over unapproved copies.
- Hims & Hers on Saturday announced it will pull its copycat weight-loss pill off the market after constructive conversations with stakeholders.
- Drugmaker Novo Nordisk responded on Thursday by threatening legal action, criticizing Hims & Hers' behaviour and citing the FDA warning about their GLP-1 product advertising, after their 2025 partnership ended.
- Priced at $49 for the first month, the pill used Wegovy's active ingredient, semaglutide, but is not FDA-approved and lacks clinical-trial proof.
- Restricting access to ingredients, the U.S. Food and Drug Administration said it plans to restrict GLP‑1 ingredients in compounded drugs, while the Department of Health and Human Services referred Hims to the Department of Justice for possible violations.
- With Super Bowl ads planned, the companies see uncertainty, as Hims' announcement could affect its ad and shares of Novo and Lilly fell.
47 Articles
47 Articles
Hims & Hers drops plan to sell Wegovy pill copy
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight‑ loss pill Wegovy on Saturday — two days after it announced the new drug following the Food and Drug Administration's threat to restrict access…
New York Post
UpstractTelehealth company scraps plans to sell cheap GLP-1 diet pill after FDA vows crackdown
Hims & Hers announced they are scrapping plans to sell a compounded version of the weight loss drug Wegovy after federal regulators vowed to take action against the telehealth provider.
Fox Business
The New York LedgerHims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
Following threats from the Food and Drug Administration (FDA) that it would take "decisive" action against companies selling "illegal copycat drugs," telehealth company Hims & Hers announced it would pull the launch of its knockoff Wegovy weight loss drug."Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry," Hims & Hers said on Saturday. "As a result, we hav…
Svenska Dagbladet
hbl.fiPharmaceutical company Hims & Hers Health is stopping sales of its slimming preparation, which is described as a cheaper copy of Danish Novo Nordisk's new Wegovy tablet.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
